MedTrace Logo

Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder

NCT05562973 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-01-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and potential efficacy of psilocybin-assisted psychotherapy to reduce post-traumatic stress disorder (PTSD) severity in a sample of individuals with PTSD.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

DRUG

Psilocybin

Participants will receive three psilocybin sessions, at least two weeks apart.

Sponsors & Collaborators

Principal Investigators

  • Matthew W Johnson, Ph.D. · Johns Hopkins University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05562973 on ClinicalTrials.gov